NRx Pharmaceuticals, Inc. (NRXPW) NASDAQ
0.01
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.01
+0(+0.00%)
Currency In USD
Address
1201 Orange Street
Wilmington, DE 19801
United States of America (the)
Phone
484 254 6134
Website
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
December 01, 2017
| Name | Title | Pay | Year Born |
| Jonathan C. Javitt | Co-Founder, Chairman & CEO | 846,774 | 1957 |
| Dennis K. McBride | Chief Strategy Officer & Director | 38,462 | 1955 |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | 240,000 | 1962 |
| Michael S. Abrams | CFO & Treasurer | 363,083 | 1970 |
| Philip T. Lavin | Chief Methodologist | 0 | 1947 |
| Suzanne Messere | Investor Relations | 0 | N/A |
| Hervé Perron | Chief Scientist | 0 | 1959 |
| Joshua C. Brown | Chief Medical Innovation Officer | 0 | N/A |
| Glenn Tyson | Chief Commercial Officer | 0 | N/A |
| Joseph Casper | Chief Operating Officer | 0 | 1951 |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.